We are your
clinical operations partner

for every service and challenge in your clinical trial lifecycle.

We contribute to the development of innovative therapies for those in need, leveraging our immunology and infectious disease experience and network.

The 'right size' CRO

Big enough to deliver,
small enough to care

Our network of internationally recognized academic leaders contribute to the design, conduct and interpretation of clinical trials in the field of immunology and vaccinology. Combined with operational excellence, this scientific expertise uniquely qualifies us as an attractive partner during the clinical development process. To customers, we are the ‘right size’ full-service clinical CRO: big enough to deliver, small enough to care.

Our profile

World-class partners

We collaborate within a vast network of leading clinics and research centers in immunology and vaccinology, offering access to world-class scientific expertise and subject populations.

Consortium specialist

We are preferred partner in several large subsidized consortium studies, funded through e.g. Horizon2020 and CEPI.

Global operations with European footprint

We manage clinical operations and partnerships globally, with a strong presence across the European continent.

Early stage specialist

We have a strong track-record of designing and managing early-stage clinical safety, feasibility and concept-efficacy projects.

Cutting-edge technology

We partner with eClinical innovators to promote research data integrity, auditability, and system interoperability, enabling us to provide best value for money to our clients.

Flexible services

We deliver custom-tailored services and adapt quickly to changing requirements.

Our services

We offer the full
range of clinical trial services

At CR2O, we have a highly motivated and experienced cross-functional team that helps you to effectively bring your project to the clinic. Our integrated project teams enable seamless transition between the domains we service.

  • Clinical Trial Management
  • Regulatory Strategy & Affairs
  • Grant Proposal Development
  • Data Management & Biostatistics
  • Pharmacovigilance & Medical Monitoring
  • Insourcing
  • Quality Management & Auditing

Overview of recently conducted clinical trials:

0
Immunology & Infectious Disease trials
0
Oncology trials
0
Other
0
Research sites
0+
Countries

A strong track-record in immunology and infectious disease

While covering a broad range of therapeutic areas, our primary expertise lies in the immunology and infectious disease domain, across all phases (I-IV). There, we have worked together with 75+ study centres across the globe. Prof. dr. Ab Osterhaus, our CSO and a world-renowned virologist, firmly believes that the development of intervention strategies for human infectious diseases can be accelerated through the clinical programs supported by CR2O.

Recent international projects with strong societal impact

  • COVID-19

    CR2O sponsors a Phase I SARS-CoV-2 monoclonal antibody clinical trial, funded by Horizon2020.
  • Influenza

    CR2O is part of a consortium that investigates next generation broad spectrum influenza vaccines through Phase I and Controlled Human Infection Model (CHIM). Funding from Horizon2020.
  • Rift Valley Fever

    CR2O sponsors a Phase I and Phase II RVFV-4s vaccine candidate. Funding from CEPI.
  • MERS Coronavirus

    CR2O co-develops a MERS-CoV candidate vaccine through Phase I and Phase II. Funding from CEPI.
  • I found CR2O to be highly professional and affordable in terms of services requested from them. CR2O has proven that they can match the delivery of expectations in the same way larger CROs can match these. I am very satisfied with the service and high quality of work CR2O delivers on our project and their ability to meet budgetary and timeline requirements.” — April 2020

    Associate Director, Global CRM Lead, Regional Clinical Research Manager
    International Pharmaceutical Company
  • Wageningen Bioveterinary Research and BunyaVax are collaborating with CR2O within the CEPI-funded LARISSA project, in which we aim to develop a human vaccine for the prevention of Rift Valley fever: a mosquito-borne disease of animals and humans. CR2O provides essential expertise on early clinical development and I much appreciate their personal involvement, enthusiasm and professional way of working. — April 2020

    CSO, Extraordinary Professor Veterinary Arbovirology, Group Head Arbovirology
    Bunyavax BV | Wageningen Bioveterinary Research (WBVR)
  • CR2O works in a very professional way and is also well up-to-date about knowledge and developments in the microbiome and probiotic field. CR2O is always open to input and suggestions from our side related to the research, by for example performing additional analyses or broaden the collaboration with other relevant parties. I am very content with the short lines in contact and the clear communication both related to the progress as well as in explaining the results.” — April 2020

    Manager Research Partnerships
    Probiotic Supplement Company
Our Partners
Executive Management

Hadil Es-Sbai, MSc

Chief Executive Officer

Prof. dr. Ab Osterhaus

Chief Scientific Officer

Bart Th. M. Bierman, MD

Chief Financial Officer